Skip to main content
The Journal of Clinical Hypertension logoLink to The Journal of Clinical Hypertension
. 2007 May 21;5(1):83–85. doi: 10.1111/j.1524-6175.2003.01923.x

Drug‐Induced Hypertension

Joel Handler 1
PMCID: PMC8099307  PMID: 12556663

A 59‐year‐old woman was evaluated in the hypertension clinic in December, 2001, for persistent stage 3 hypertension. She had a 12‐year history of hypertension controlled on hydrochlorothiazide monotherapy. However, blood pressure had increased, progressing for approximately 6 months prior to her consultation visit and was refractory to the addition of clonidine and felodipine to her regimen. Some leg swelling and a few episodes of rapid heart beat had been noted. Home and clinic pressures of 180–200/80–110 mm Hg were observed.

Her primary physician had prescribed acetaminophen for osteoarthritic knee discomfort, but the patient's brother, a physician, had also prescribed celecoxib 200 μg q.d. Furthermore, the patient admitted to taking various herbal products for her arthritic condition and to enhance her well‐being.

Physical examination revealed an overweight female with a blood pressure of 182/94 mm Hg and a heart rate of 100 beats/min. Heart and lung examinations were normal except for some tachycardia; there were no bruits. Additionally, 1–2+ankle edema was noted. Urinalysis revealed no proteinuria, and serum creatinine was 1.2 mg/dL.

It had not been apparent that the patient was taking celecoxib along with herbal remedies, but when requested to bring in all of her prescription medications, and questioned about herbal products, the extent of her polypharmacy was realized. One of the herbal concoctions contained ginger root. On stopping the celecoxib and herbal formula, a followup blood pressure 3 weeks later was 138/86 mm Hg. Removal of felodipine led to resolution of her edema and palpitations, and she no longer required clonidine.

Two meta‐analyses have noted a modest hypertensive effect of nonsteroidal anti‐inflammatory agents for individuals already on antihypertensive medications. 1 , 2 In one meta‐analysis, 1 the mean arterial pressure increase was 6.10 mm for naproxen, 4.77 mm for indomethacin, and 2.86 mm for piroxicam, compared to 2.20 mm for sulindac and −0.30 mm for ibuprofen. In the second meta‐analysis, 2 only piroxicam produced a statistically significant increase in mean supine pressure of 6.2 mm and, again, sulindac had the least effect. There was a greater increase in blood pressure when nonsteroidal anti‐inflammatory medications were prescribed concomitantly with β blockers compared with vasodilators and diuretics. 2

The mechanism of nonsteroidal effect possibly is related to the inhibition of synthesis of vasodilatory and natriuretic prostaglandins. 3 While for the most part, the worsening of hypertension by the cyclooxygenase‐2 inhibitor class of nonsteroidal anti‐inflammatory drugs is also modest, cases of more exaggerated effect have been reported. 4 Therefore, the reversibility of the hypertension for the patient under discussion probably was entirely due to the removal of celecoxib.

Ginger root is primarily used for dyspepsia and travel sickness but is also thought to possess anti‐inflammatory effects. 5 The patient under discussion thought she derived some arthritis relief, but stopping the herbal supplement did not result in any change in her condition. While hypertensive effects have not been reported in humans, pressor effects due to ginger have been observed in animal studies. 6

Pathophysiologic changes have been described for medication‐induced hypertension for several substances (alcohol, licorice, ma huang), may be a mild long‐term effect of varying frequency for some medications (nonsteroidal anti‐inflammatory agents, erythropoietin, cyclosporine, oral contraceptives), is dose‐related for venlafaxine, and may occur almost entirely in patients with preexisting hypertension (sibutramine, carbamazepine). Hypertensive effects may be exhibited only in high catecholamine states, such as the paradoxical propranolol effect in hypoglycemic diabetic patients, or it may be quite transient (nicotine). Occasionally, high blood pressure occurs with drug discontinuation at higher dosages of clonidine and methyldopa. In many instances, the associations are rare. Substances and medications that have been associated with blood pressure elevation are listed in the Table.

Many times we take away these medications in our hypertensive patients without any result. However, it is wise to take a survey of possible alternative sources of medications along with store‐bought substances, particularly for an individual who develops a new sustained rise in previously controlled blood pressure.

Table.

Medications/Substances Implicated With Blood Pressure Elevation

Herbs/Substances
Alcohol, probable central mechanism 7
Amphetamines
Arsenic
Cadmium, acute intoxication, possible occupational exposure in battery factory 8
Caffeine, very mild effect 9 , 10
Cigarette smoking, BP may surge up to 30 minutes, may interfere with treatment 11 , 12
Cocaine
Ethylene glycol exposure, usually diastolic hypertension 8
Ginger, animal studies 6
Ginseng, abuse syndrome 6
Glucosamine, usually in diabetics 13
Lead, acute intoxication 8
Licorice, mimic of primary hyperaldosteronism 8
Ma Huang, herbal source of ephedrine 14 , 15
Spider bites (black widow), scorpion bites, associated with bradycardia 8
M edications
Aldomet, when added to propranolol 16
Anabolic steroids, mild dose‐related hypertensive effect 8
Bromocriptine, cases of severe hypertension 8
Bupropion, may exacerbate baseline hypertension 17
Carbamazepine, may aggravate hypertension 18
Clonidine, rebound withdrawal generally at doses >1.2 ì/day 19
Clozapine, pseudopheochromocytoma syndrome 19
Cyclosporin, increased volume retention and renal afferent arteriolar construction; BP up in 25%–30% of nontransplant and 50%–80% of solid organ transplant patients 20 , 21
Danazol, mild dose effect 8
Disulfiram, slight BP effect 8
Ergot alkaloids, vasoconstriction 8
Erythropoietin, SVR increase, BP effect usually within 3 months of dialysis initiation, nonprecise correlation with hematocrit rise 21 , 22
Fentanyl, transient BP rise 8
Fluoxetine, serotonin syndrome with MAOIs 23
Glucagon, when used for GI and radiologic procedures 8
Glucocorticoids, affecting both circulating volume and vascular resistance 24
Indinavir, poor retrospective study 25
Ketamine, may be a transient severe BP elevation 8
Ketoconazole, mimic of primary hyperaldosteronism 8
Leflunomide, new disease‐modifying drug for rheumatoid arthritis 26
Levodopa, following suicidal ingestion 8
MAOIs, interaction effect with over‐the‐counter medications and high tyramine foods 8
Meperidine, serotonin syndrome with MAOIs 23
Methylphenidate
Mineralocorticoids, even topical administration may cause hypertension associated with hypokalemia, alkalosis, and low renin/aldosterone levels 8
Naloxone, transient BP rise 8
NSAIDs, mild effect in two meta‐analyses 1 , 2
Oral contraceptives, mild sustained hypertension may be severe 8
Phenylpropanolamine, removed from market 27
Pindolol, related to intrinsic sympathomimetic activity 8
Propranolol, rare paradoxical reactions, especially in hypoglycemic diabetics 28 , 29 , 30
Ritodrine
Sibutramine
SSRIs, serotonin syndrome with MAOIs 31
TCAs, though these agents are more commonly associated with postural hypotension 8
Testosterone, topical application in one case report associated with hematocrit rise 32
Yohimbine, acute dose‐dependent BP effect 8
Venlafaxine, dose related nonadrenergic BP effect 33
BP=blood pressure; SVR=systemic vascular resistance; MAOIs=monoamine oxidase inhibitors; GI=gastrointestinal; NSAIDs=nonsteroidal anti‐inflammatory drug; SSRIs=selective seratonin reuptake inhibitor; TCAs=tricyclic antidepressants

References

  • 1. Pope JE, Anderson JJ, Felson DT. A meta‐analysis of the effects of nonsteroidal anti‐inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477–484. [PubMed] [Google Scholar]
  • 2. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti‐inflammatory drugs affect blood pressure? A meta‐analysis. Ann Intern Med. 1994;121:289–300. [DOI] [PubMed] [Google Scholar]
  • 3. Brook RD, Kramer MB, Blaxall BC, et al. Nonsteroidal anti‐inflammatory drugs and hypertension. J Clin Hypertens. 2000;2(5):319–323. [PubMed] [Google Scholar]
  • 4. Graves JW, Hunder IA. Worsening of hypertension by cyclooxygenase‐2 inhibitors. J Clin Hypertens. 2000;2(6):396–398. [Google Scholar]
  • 5. PDR for Herbal Medicines. 2nd ed. Montvale , NJ : Medical Economics Company; 2000:339–342. [Google Scholar]
  • 6. Valli G, Giardina EGV. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol. 2002;39:1083–1095. [DOI] [PubMed] [Google Scholar]
  • 7. Randin D, Vollenweider P, Tappy L. Suppression of alcohol‐induced hypertension by dexamethasone. N Engl J Med. 1995;332:1733–1737. [DOI] [PubMed] [Google Scholar]
  • 8. Grossman E, Messerli FH. High blood pressure, a side effect of drugs, poisons, and food. Arch Intern Med. 1995;155:450–460. [DOI] [PubMed] [Google Scholar]
  • 9. Hee SA, Jiang H, Whelton PK, et al. The effect of chronic coffee drinking on blood pressure: a meta‐analysis of controlled clinical trials. Hypertension. 1999;33:647–652. [DOI] [PubMed] [Google Scholar]
  • 10. Klag MJ, Wang NH, Meoni LA, et al. Coffee intake and risk of hypertension. The Johns Hopkins Precursors Study. Arch Intern Med. 2002;162:657–662. [DOI] [PubMed] [Google Scholar]
  • 11. Groppelli A, Giorgi DM, Ombroni S, et al. Persistent blood pressure increase induced by heavy smoking. J Hypertens. 1992;10:495–499. [DOI] [PubMed] [Google Scholar]
  • 12. Materson BJ, Reda D, Fries ED, et al. Cigarette smoking interferes with treatment of hypertension. Arch Int Med. 1988;148:2116–2119. [PubMed] [Google Scholar]
  • 13. Bove AA. Dietary supplements in athletes. ACC Curr J Rev. 2002;11:18–20. [Google Scholar]
  • 14. Samenuk D, Link MS, Houd MK, et al. Adverse cardiovascular events temporarily associated with ma huang, and herbal source of ephedrine. Mayo Clin Proc. 2002;77: 12–16. [DOI] [PubMed] [Google Scholar]
  • 15. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343:1833–1838. [DOI] [PubMed] [Google Scholar]
  • 16. Nies AS, Shand DG. Hypertensive response to propranolol in a patient treated with methyldopa: a proposed mechanism. Clin Pharmacol Ther. 1973;14:923. [DOI] [PubMed] [Google Scholar]
  • 17. Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bypropion in depressed patients with heart disease. Am J Psychiatry. 1991;148:512–516. [DOI] [PubMed] [Google Scholar]
  • 18. Carbamazepine, Tegretol. In: Physicians' Desk Reference, 57th ed. Medical Economics Company; 2003:2325. [Google Scholar]
  • 19. Houston MC. Clonidine hydrochloride. S Med J. 1982;75:713–721. [DOI] [PubMed] [Google Scholar]
  • 20. Krentz A. Pseudophaeochromocytoma syndrome associated with clozapine. BMJ. 2001;322:123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413–2446. [DOI] [PubMed] [Google Scholar]
  • 22. Buckner FS, Eschbach JW, Haley R, et al. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens. 1990;3:947–955. [DOI] [PubMed] [Google Scholar]
  • 23. Ruiz F. Fluoxitene and the serotonin syndrome. Ann Emerg Med. 1994;24:983–985. [DOI] [PubMed] [Google Scholar]
  • 24. Brem AS. Insights into glucocorticoid‐associated hypertension. Am J Kid Dis. 2001;37:1–9. [DOI] [PubMed] [Google Scholar]
  • 25. Cattelan AM, Trvenzoli M, Sasset L, et al. Indinacir and systemic hypertension. AIDS. 2001;15:805–807. [DOI] [PubMed] [Google Scholar]
  • 26. Rozman B, Praprotnik S, Logar D, et al. Leflunomide and hypertension. Ann Rheum Dis. 2002;51:567–569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343:1826–1832. [DOI] [PubMed] [Google Scholar]
  • 28. Lloyd‐Mostyn RH, Oram S. Modification by propranalol of cardiovascular effects of induced hypoglycemia. Lancet. 1975;1:1213–1215. [DOI] [PubMed] [Google Scholar]
  • 29. Drayer J, Keim JH, Weber MA, et al. Unexpected pressor response to propranolol in essential hypertension. Am J Med. 1976;60:987–993. [DOI] [PubMed] [Google Scholar]
  • 30. Blum I, Atsmon A, Steiner M. Paradoxical rise in blood pressure during propranolol treatment. BMJ. 1975;1:623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Martin TG. Serotonin syndrome. Ann Emerg Med. 1996;28:520–526. [DOI] [PubMed] [Google Scholar]
  • 32. Tangredi JF, Buxton ILO. Hypertension as a complication of topical testosterone therapy. Ann Pharmacother. 2001;35:1205–1207. [DOI] [PubMed] [Google Scholar]
  • 33. Meyers BS. Depression and other mood disorders. In: Cobbs EL, Duthie EH, Murphy JB, eds. Geriatric Review Syllabus, 5th ed. Malden , MA ; Blackwell Publishing: 2002. [Google Scholar]

Articles from The Journal of Clinical Hypertension are provided here courtesy of Wiley

RESOURCES